ERBB2 and neoplasm: However, T-DM1 treatment, compared with CL, reduced the risk of PD to a similar degree regardless of tumor ERBB2 mRNA levels and tests for interaction between treatment and ERBB2 mRNA levels were not statistically significant (p = 0.07).